Boditech Med Inc. (206640.KQ)
KRW 16600.0
(0.36%)
KRW 16600.0
(0.36%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 36.48 Billion KRW | 13.71% |
| 2022 | 32.14 Billion KRW | -45.68% |
| 2021 | 57.97 Billion KRW | -20.15% |
| 2020 | 71.4 Billion KRW | 307.62% |
| 2019 | 20.15 Billion KRW | 63.77% |
| 2018 | 10.63 Billion KRW | 63.52% |
| 2017 | 6.5 Billion KRW | -56.15% |
| 2016 | 14.82 Billion KRW | 6.28% |
| 2015 | 13.95 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 7.84 Billion KRW | 8.06% |
| 2024 Q2 | 10.75 Billion KRW | 72.49% |
| 2023 Q2 | 9.58 Billion KRW | 42.36% |
| 2023 FY | - KRW | 13.71% |
| 2023 Q3 | 10.42 Billion KRW | 8.71% |
| 2023 Q1 | 6.73 Billion KRW | -25.38% |
| 2023 Q4 | 8.25 Billion KRW | -20.79% |
| 2022 FY | - KRW | -45.68% |
| 2022 Q1 | 10.44 Billion KRW | 45.7% |
| 2022 Q2 | 4.7 Billion KRW | -54.94% |
| 2022 Q3 | 8.34 Billion KRW | 77.35% |
| 2022 Q4 | 9.02 Billion KRW | 8.13% |
| 2021 FY | - KRW | -20.15% |
| 2021 Q3 | 17.32 Billion KRW | -5.5% |
| 2021 Q1 | 14.6 Billion KRW | -52.18% |
| 2021 Q2 | 18.33 Billion KRW | 25.53% |
| 2021 Q4 | 7.17 Billion KRW | -58.61% |
| 2020 Q2 | 16.31 Billion KRW | 343.28% |
| 2020 FY | - KRW | 307.62% |
| 2020 Q4 | 30.54 Billion KRW | 46.36% |
| 2020 Q3 | 20.86 Billion KRW | 27.87% |
| 2020 Q1 | 3.68 Billion KRW | -37.71% |
| 2019 Q4 | 5.91 Billion KRW | 10.93% |
| 2019 FY | - KRW | 63.77% |
| 2019 Q1 | 4.86 Billion KRW | 25.75% |
| 2019 Q2 | 3.99 Billion KRW | -17.97% |
| 2019 Q3 | 5.32 Billion KRW | 33.43% |
| 2018 FY | - KRW | 63.52% |
| 2018 Q4 | 3.87 Billion KRW | 28.5% |
| 2018 Q2 | 2.33 Billion KRW | 65.64% |
| 2018 Q3 | 3.01 Billion KRW | 28.85% |
| 2018 Q1 | 1.41 Billion KRW | 677.17% |
| 2017 Q2 | 2.46 Billion KRW | -28.25% |
| 2017 Q1 | 3.43 Billion KRW | 55.17% |
| 2017 FY | - KRW | -56.15% |
| 2017 Q4 | -244.53 Million KRW | -128.89% |
| 2017 Q3 | 846.39 Million KRW | -65.66% |
| 2016 Q2 | 4.85 Billion KRW | 61.71% |
| 2016 Q4 | 2.21 Billion KRW | -53.5% |
| 2016 Q1 | 3 Billion KRW | -16.67% |
| 2016 Q3 | 4.76 Billion KRW | -1.86% |
| 2016 FY | - KRW | 6.28% |
| 2015 Q4 | 3.6 Billion KRW | -18.14% |
| 2015 FY | - KRW | 0.0% |
| 2015 Q3 | 4.39 Billion KRW | 16.73% |
| 2015 Q1 | 2.18 Billion KRW | 0.0% |
| 2015 Q2 | 3.76 Billion KRW | 72.54% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | -6179.321% |
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | -552.221% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | 32.708% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 75.983% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | 58.856% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 731.978% |
| Humedix Co., Ltd. | 54.87 Billion KRW | 33.505% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | 930.829% |
| FutureChem Co.,Ltd | -591.25 Million KRW | 6271.356% |
| Huons Co., Ltd. | 74.23 Billion KRW | 50.846% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | -157.478% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 380.582% |